Kyverna Therapeutics, Inc.

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases. Its lead program, KYV-101, is being advanced in late-stage trials for conditions such as myasthenia gravis, stiff person syndrome, and lupus nephritis, with additional exploration in multiple sclerosis.

7.75

7.75

— Kyverna Therapeutics, Inc.
%
Lead cell therapy programs0% Clinical-stage autologous cell therapy candidates designed to reset autoimmune disease activity.
Pipeline expansion programs0% Earlier-stage and additional indications built around the same autoimmune cell therapy platform.
Manufacturing and process development0% Third-party cell manufacturing, release testing, and vector process development supporting trials.
Collaboration and licensing activities0% Strategic alliances and licensing arrangements used to fund and extend the pipeline.

Kyverna does not yet sell approved products; its direct 'customers' are primarily clinical trial patients and the...

  • Clinical trial patientsprimary

    Patients with autoimmune diseases enrolled in KYV-101 and related studies to evaluate safety and efficacy.

  • Investigators and trial sitesprimary

    Hospitals, academic centers, and clinicians that recruit patients, administer protocols, and generate data.

  • Specialist prescriberssecondary

    Neurology and nephrology specialists who would drive adoption if the therapies are approved.

  • Manufacturing and development partnersprimary

    CMOs and vector suppliers that provide cell manufacturing, release testing, and process development.

  • Strategic collaboratorssecondary

    Potential licensing or alliance partners that can provide capital, expertise, or commercialization support.

Kyverna is headquartered in the United States and its operating footprint is centered on U.S...

  • •United States is the core market for trials, operations, and future commercialization
  • •Emeryville, California houses office and laboratory operations
  • •Philadelphia, Pennsylvania supports customized cell manufacturing and testing
  • •United Kingdom supply chain exposure through Oxford Biomedica
  • •Future international expansion is mentioned but not yet a major revenue driver

Kyverna is focused on advancing KYV-101 through late-stage clinical development and preparing for regulatory filings,...

01
Complete late-stage development of KYV-101short-term

Regulatory success depends on generating pivotal data in myasthenia gravis and stiff person syndrome.

02
Broaden the pipeline beyond KYV-101medium-term

A broader autoimmune portfolio reduces single-asset dependence and increases long-term value creation.

03
Build commercial and manufacturing readinessmedium-term

Cell therapies require specialized supply, release testing, and launch infrastructure before approval.

Kyverna is a pre-revenue biotech with a limited operating history, substantial accumulated losses, and ongoing...

critical

Clinical development failure or delay

The company’s value depends on positive data and timely enrollment in KYV-101 trials.

Scope
KYSA-6, KYSA-1, KYSA-3, KYV-102
Materiality
high
high

Financing and liquidity risk

The company has recurring losses and may need equity, debt, or partnership funding to continue operations.

Scope
General corporate funding and trial execution
Materiality
high
high

Third-party manufacturing dependence

Cell therapy supply relies on CMOs and vector partners, reducing control over quality, timing, and cost.

Scope
MAT, Advanced Therapies, ElevateBio, Oxford Biomedica
Materiality
high
high

Regulatory and approval risk

Late-stage programs must satisfy FDA and other regulators before commercialization can begin.

Scope
BLA filing, Phase 3 initiation, orphan/RMAT pathways
Materiality
high
medium

Competitive and IP risk

Competing autoimmune therapies and patent challenges could reduce market opportunity and exclusivity.

Scope
Autoimmune cell therapy landscape
Materiality
medium
R&D expense accruals
Trial timing can shift reported losses materially
Lease accounting
Emeryville lab lease and equipment leases
Stock-based compensation
Impacts operating loss and comparability
Going-concern and liquidity assumptions
Important for assessing dilution and execution risk

Kymera Therapeutics, Inc.

KYMR · Biological Products, (No Diagnostic Substances)

ZyVersa Therapeutics, Inc.

ZVSA · Pharmaceutical Preparations

Coya Therapeutics, Inc.

COYA · Pharmaceutical Preparations

Spyre Therapeutics, Inc.

SYRE · Pharmaceutical Preparations

Taysha Gene Therapies, Inc.

TSHA · Biological Products, (No Diagnostic Substances)

KIORA PHARMACEUTICALS INC

KPRX · Pharmaceutical Preparations

: 28/04/2026